- Reaction score
- 365
A private company like histogen struggles to conjured the 10-20 million necessary for phase III trials alone. Developing the drug through phase I and phase II costs money too. The cost of one mediocre researcher probably starts at 250,000/year once you include taxes, office space, and overhead.
It's not up to small companies to research. Brotzu found this by fluke.
And there's no need for a conspiracy.
Sure, but the reason that private companies have difficulty attaining funding is because researchers are still learning about hairloss and all the different pathways in the body that are affected. If I was a wealthy investor, I wouldn't be confident trying to buck the trend in an industry that only has two FDA approved methods of action - both discovered accidentally by the way - since the 80's. The science being murky has been what's kept big time investors away most likely. If there were a bald billionaire somewhere who hated his hairloss and was convinced in the science behind hair regeneration, he'd put down $100 mil knowing the returns are in the tens of billions if it works out. It's just the fact that male pattern baldness is a tricky son of a b**ch.